What is the recommended treatment protocol for hyperkalemia in hospitalized patients?

Treatment of Hyperkalemia in the Hospital

For hospitalized patients with acute hyperkalemia, immediately administer 10 mL of 10% intravenous calcium gluconate if ECG changes are present or potassium is markedly elevated, followed by 10 units IV insulin with 50 mL dextrose and nebulized salbutamol 20 mg, then initiate early potassium binder therapy—preferably sodium zirconium cyclosilicate or patiromer—rather than sodium polystyrene sulfonate. 1

Immediate Cardiac Stabilization (1-3 minutes)

For patients with ECG changes or severe hyperkalemia:

• Administer 10 mL of 10% IV calcium gluconate immediately to stabilize cardiac membrane excitability 2, 1
• Repeat the calcium dose if no ECG improvement occurs within 5-10 minutes 1
• Maintain continuous ECG monitoring, recognizing that peaked T waves and QRS widening are variable and less sensitive than laboratory values 1
• Note that calcium does not lower total body potassium but prevents life-threatening arrhythmias 2

Intracellular Potassium Shift (30-60 minutes onset)

To temporarily redistribute potassium:

• Give 10 units IV regular insulin with 50 mL dextrose to drive potassium intracellularly 2, 1
• Always co-administer glucose with insulin to prevent hypoglycemia 1
• Add nebulized salbutamol 20 mg in 4 mL as an adjunct for additional intracellular shift 2, 1
• Recognize that β-agonists have a short duration of effect (2-4 hours) and rebound hyperkalemia typically occurs ~2 hours after these agents 2, 1
• Reserve IV sodium bicarbonate exclusively for patients with concurrent metabolic acidosis, as it promotes urinary potassium excretion 2, 1

Critical pitfall: Insulin, salbutamol, and bicarbonate provide only temporary shifts lasting 1-4 hours without removing potassium from the body, necessitating early binder initiation to prevent rebound 1

Potassium Elimination Strategies

Diuretics

• Use loop diuretics in hypervolemic, non-oliguric patients to increase renal potassium loss 2, 1
• Effectiveness depends on residual kidney function 2

Hemodialysis

• Initiate hemodialysis for refractory acute hyperkalemia, oliguria, or end-stage renal disease 2, 1
• Hemodialysis increases total potassium elimination when other measures fail 2

Potassium Binders (First-Line for Elimination)

Sodium Zirconium Cyclosilicate (SZC) - Preferred:

• Onset of potassium-lowering effect is as fast as 1 hour with high selectivity for potassium 1
• Acute regimen: 10 g three times daily for 48 hours 1
• Maintenance dosing: 5-15 g once daily, titrated to maintain serum potassium 3.5-5.0 mEq/L 1
• Acts throughout the small and large intestines 1
• Adverse effects include constipation, diarrhea, nausea, and mild-to-moderate edema 1
• Each 5 g dose contains approximately 400 mg of sodium 1
• Single-dose SZC 10 g achieved normokalemia in 58.1% of hospitalized patients with asymptomatic hyperkalemia within 12-30 hours 3

Patiromer - Alternative:

• Potassium-lowering onset is approximately 7 hours via calcium-for-potassium exchange in the colon 1
• Starting dose: 8.4 g once daily, titratable up to 25.2 g daily 1
• Separate patiromer from other oral medications by at least 3 hours to avoid drug-binding interactions 1
• Common adverse effects include gastrointestinal discomfort, hypomagnesemia, and rare hypercalcemia 1
• Each 8.4 g dose provides approximately 1.6 g of calcium; monitor calcium levels 1

Sodium Polystyrene Sulfonate (SPS) - NOT Recommended:

• SPS is linked to intestinal ischemia, colonic necrosis, and a 33% mortality rate in affected patients 1
• Efficacy is inconsistent with onset ranging from hours to days, and long-term data are lacking 1
• Non-selective ion binding can cause hypocalcemia and hypomagnesemia 1
• Despite these risks, SPS was used in 95% of treatment regimens in one observational study, though this reflects outdated practice patterns 4

RAAS Inhibitor Management During Hyperkalemia

The priority is maintaining RAAS inhibitor therapy, not discontinuing it:

• Continuing RAAS inhibitors reduces mortality and major adverse cardiovascular events compared with discontinuation, even when kidney function declines 1
• Maximum tolerated RAAS inhibitor therapy should be maintained whenever clinically indicated 2, 1
• If hyperkalemia develops, treat first with potassium binders rather than reducing the RAAS inhibitor dose 1
• After acute hyperkalemia resolves, re-initiate any discontinued RAAS inhibitor and reassess serum potassium within one week 2, 1
• Identify and mitigate other hyperkalemia contributors including NSAIDs, potassium supplements, and high-potassium diet 2, 1
• Utilize newer potassium binders (patiromer or SZC) to enable optimal RAAS inhibitor dosing 1, 5

Monitoring and Potassium Thresholds

Laboratory considerations:

• Serum potassium ≥5.5 mEq/L is widely accepted as the hyperkalemia threshold, though adverse outcomes occur at levels >5.0 mEq/L in heart failure and CKD populations 2, 1
• Plasma potassium values are 0.1-0.4 mEq/L lower than serum values due to platelet potassium release during clotting 2, 1
• Exclude pseudohyperkalemia caused by fist clenching, hemolysis, or delayed specimen processing before initiating treatment 2, 1
• Clinical decision-making should prioritize rapid potassium fluctuations and overall patient status rather than rigid adherence to a single numeric threshold 2, 1

Follow-up monitoring:

• Measure potassium within one week of initiating or up-titrating a RAAS inhibitor 2, 1
• Increase monitoring frequency in patients with CKD, diabetes, heart failure, or prior hyperkalemia episodes 1

Treatment Algorithm by Clinical Scenario

Severe hyperkalemia with ECG changes:

1. IV calcium gluconate 10 mL of 10% immediately 1
2. IV insulin 10 units + dextrose 50 mL 1
3. Nebulized salbutamol 20 mg 1
4. Initiate SZC 10 g three times daily for 48 hours 1
5. Consider hemodialysis if refractory or oliguric 1

Moderate hyperkalemia (5.5-6.4 mEq/L) without ECG changes:

1. IV insulin 10 units + dextrose 50 mL 2, 1
2. Nebulized salbutamol 20 mg 2, 1
3. Initiate SZC 10 g three times daily or patiromer 8.4 g daily 1
4. Loop diuretics if hypervolemic and non-oliguric 1

Mild hyperkalemia (5.1-5.4 mEq/L):

• Most patients (>74.5%) achieve normokalemia without active treatment 6
• However, early binder therapy (SZC or patiromer) is reasonable to facilitate RAAS inhibitor continuation 1
• Identify and remove contributing factors (NSAIDs, potassium supplements, dietary potassium) 2, 1

Chronic/recurrent hyperkalemia:

• Maintenance SZC 5-15 g daily or patiromer 8.4-25.2 g daily 1
• Optimize RAAS inhibitor dosing while maintaining potassium 3.5-5.0 mEq/L 1
• Weekly potassium monitoring initially, then adjust based on stability 2, 1